ALK udvider partnerskab med Torii i Japan
December 12, 2023 10:08 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) og selskabets japanske partner Torii Pharmaceutical Co., Ltd. (’Torii’) meddeler i dag, at de har udvidet samarbejdet og har indgået yderligere en licensaftale, der...
ALK expands partnership with Torii in Japan
December 12, 2023 10:08 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) and its Japanese partner Torii Pharmaceutical Co., Ltd. ('Torii') today announced that they have expanded their collaboration and entered into an additional license...
Nine-month interim report (Q3) 2023
November 15, 2023 01:30 ET
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led...
Nine-month interim report (Q3) 2023
November 15, 2023 01:30 ET
|
ALK Abello
ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales...
Dato for offentliggørelse af delårsrapport for første ni måneder (Q3) 2023 for ALK og webcast
November 09, 2023 07:46 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for første ni måneder (Q3) 2023 onsdag den 15. november 2023. ALK afholder samme dag kl. 13.30 (CET) en telekonference for investorer...
Release date of nine-month interim report (Q3) 2023 for ALK and audio cast
November 09, 2023 07:46 ET
|
ALK Abello
On Wednesday, 15 November 2023 ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its nine-month interim report (Q3) 2023. ALK will host a meeting for analysts and institutional investors that day at 1.30pm...
Stort klinisk fase 3-studie når sit primære endemål og bekræfter potentialet af ALK’s tabletvaccine mod træpollenallergi til børn
October 11, 2023 10:13 ET
|
ALK Abello
Fase 3 effekt- og sikkerhedsstudiet med ALK’s tabletvaccine mod træpollenallergi omfattede 952 børn i alderen 5 til 17 år i Canada og EuropaALK har nu succesfuldt fuldført den kliniske udvikling af...
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
October 11, 2023 10:13 ET
|
ALK Abello
The Phase 3 efficacy and safety trial of ALK’s tree tablet involved 952 children aged 5 to 17 in Canada and Europe.ALK has now successfully completed pivotal clinical development for all five...
Six-month interim report (Q2) 2023
August 24, 2023 01:30 ET
|
ALK Abello
Bemærk venligst, at rapporten udelukkende forefindes på engelsk ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by...
Six-month interim report (Q2) 2023
August 24, 2023 01:30 ET
|
ALK Abello
ALK delivers 11% revenue growth with operating profit up 120% in Q2 (unaudited) ALK’s revenue grew by 11% in Q2 2023, driven by 17% growth in tablet sales and...